title: The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.
abstract: Neutrophil chemotaxis has been shown to be regulated by two different signalling pathways that allow strong chemoattractants, such as bacterial-derived formylated peptides, to dominate over endogenous attractants, such as interleukin-8 (IL-8). Here we show that triggering of the formyl peptide receptor (FPR) with f-Met-Leu-Phe (fMLF) substantially reduced the neutrophil superoxide production induced by activation of the CXC receptors with IL-8. When the order of agonists was reversed, the cells were primed in their response to fMLF, suggesting that the signalling hierarchy between strong, so-called end-type (i.e. fMLF) and weak or intermediate-type (i.e. IL-8) chemoattractants, is also operating during activation of the NADPH-oxidase. The same result was obtained when fMLF was replaced with the hexapeptide, WKYMVM, specific for the formyl peptide-like receptor 1 (FPRL1). There were additional differences between the agonist receptor pairs fMLF/FPR, WKYMVM/FPRL1 and IL-8/CXCR. In contrast to FPR and FPRL1, no reserve pool of CXCR was present in subcellular granules and it was impossible to prime the oxidative response transduced through CXCR by the addition of priming agents such as tumour necrosis factor-alpha and platelet-activating factor. Moreover, the cytoskeleton-disrupting substance, cytochalasin B, had no effect either on IL-8-triggered oxidase activation or on CXCR reactivation. A pertussis toxin-sensitive G-protein is involved in signalling mediated through both FPR and CXCR, and the signalling cascades include a transient intracellular calcium increase, as well as downstream p38 MAPK and phosphoinositide 3-kinase activation. The data presented in this study provide support for two different signalling pathways to the neutrophil NADPH-oxidase, used by ligand binding to FPR/FPRL1 or CXCR, respectively.
authors.affiliation: Department of Rheumatology and Inflammation Research, University of Göteborg, Göteborg, Sweden. Huamei.fu@microbio.gu.se
authors.forename: Huamei
authors.initials: H
authors.lastname: Fu
authors.forename: Johan
authors.initials: J
authors.lastname: Bylund
authors.forename: Anna
authors.initials: A
authors.lastname: Karlsson
authors.forename: Sara
authors.initials: S
authors.lastname: Pellmé
authors.forename: Claes
authors.initials: C
authors.lastname: Dahlgren
mesh_terms: D000328:Adult; D002478:Cells, Cultured; D002630:Chemotactic Factors / Q000276:immunology*; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D003599:Cytoskeleton / Q000378:metabolism; D004789:Enzyme Activation / Q000276:immunology; D006801:Humans; D016209:Interleukin-8 / Q000276:immunology*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000276:immunology; D019255:NADPH Oxidases / Q000378:metabolism*; D018375:Neutrophil Activation; D009504:Neutrophils / Q000201:enzymology* / Q000276:immunology; D009842:Oligopeptides / Q000276:immunology; D010972:Platelet Activating Factor / Q000276:immunology; D044042:Receptors, Formyl Peptide / Q000276:immunology; D023062:Receptors, Interleukin-8A / Q000378:metabolism; D023063:Receptors, Interleukin-8B / Q000378:metabolism; D015398:Signal Transduction / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D002630:Chemotactic Factors; D016209:Interleukin-8; D009842:Oligopeptides; D010972:Platelet Activating Factor; D044042:Receptors, Formyl Peptide; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B; C113617:Trp-Lys-Tyr-Met-Val-Met; D014409:Tumor Necrosis Factor-alpha; D009240:N-Formylmethionine Leucyl-Phenylalanine; D019255:NADPH Oxidases